High-flying Samsung Biologics inks $1B production pact with unnamed US pharma

As Samsung Biologics continues to ink production pacts around the globe, the company has added another billion-dollar feather to its cap. In a public disclosure, Samsung Biologics revealed a new manufacturing accord with a large, unnamed U.S. drugmaker worth about $1.05 billion.

As Samsung Biologics continues to ink production pacts around the globe, the company has added another billion-dollar feather to its cap. In a public disclosure, Samsung Biologics revealed a new manufacturing accord with a large, unnamed U.S. drugmaker worth about $1.05 billion.
Share article
Related Content